counter-ion raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-07-21 and is reviewed periodically as new material appears.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
=== Mycolic acid analysis === Mycolic acid analysis has been an evolving field of study for gas-liquid chromatography, as it offers a solution to slow growth rates in Mycobacterium. Mycolic acid is a fatty acid found in the disease tuberculosis, offering a chemical target for diagnosticians to look for.
== Distribution and habitat == The species is widespread in temperate forests of the Northern Hemisphere. In North America, it can be found from August to November. It is a white-rot wood-decay fungus on conifer wood, particularly hemlock (genus Tsuga).
=== 2017 === On 29 September 2017, BSAT-4a, dedicated for UHDTV programming and was also claimed "the world's first 8K satellite", was launched from the Guiana Space Centre aboard Ariane 5 rocket. BSAT-4a would be used for 2020 Summer Olympics held in Japan. Additionally, in September 2017, Kaleidescape, a manufacturer of home-theater movie players and servers made 4K UHD movies compatible with their movie store, and with their movie players. In December 2017, Qualcomm announced that their Snapdragon 845 chipset and Spectra 280 Image Signal Processor would be the first phone SoC to record video in UHD Premium.
== Awards == 2009: BBSRC David Phillips Fellowship 2012: ERC Starting Grant 2014: Talented Young Italians Award (Research and Innovation) 2015: EFMC Prize for Young Medicinal Chemist in Academia 2015: ICBS Young Chemical Biologist Award 2016: RSC Capps Green Zomaya Award 2016: MedChemComm Emerging Investigator Lectureship 2016: Fellow of the Royal Society of Chemistry (FRSC) 2022: Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery 2023: Fellow of the Royal Society of Edinburgh (FRSE) 2025: Fellow of the Royal Society 2026: Fellow of the Academy of Medical Sciences (FMedSci)
Thus, decaffeination of tea requires more care to maintain tannin content than decaffeination of coffee in order to preserve this flavor. Preserving tannins is desirable not only because of their flavor, but also because they have been shown to have anticarcinogenic, antimutagenic, antioxidative, and antimicrobial properties. Specifically, tannins accelerate blood clotting, reduce blood pressure, decrease the serum lipid level, and modulate immunoresponses. Certain processes during normal production might help to decrease the caffeine content directly, or simply lower the rate at which it is released throughout each infusion. In China, this is evident in many cooked pu-erh teas, as well as more heavily fired Wuyi Mountain oolongs; commonly referred to as 'zhonghuo' (mid-fired) or 'zuhuo' (high-fired). A generally accepted statistic is that a cup of normal black (or red) tea contains 40–50 mg of caffeine, roughly half the content of a cup of coffee. Although a common technique of discarding a short (30 to 60 seconds) steep is believed to much reduce caffeine content of a subsequent brew at the cost of some loss of flavor, research suggests that a five-minute steep yields up to 70% of the caffeine, and a second steep has one-third the caffeine of the first (about 23% of the total caffeine in the leaves).
Sources: en.wikipedia.org
=== High-resolution melting of the entire amplicon === High-resolution melting analysis is the simplest PCR-based method to understand. Basically, the same thermodynamic properties that allowed for the gel techniques to work apply here, and in real-time. A fluorimeter monitors the post-PCR denaturation of the entire dsDNA amplicon. You make primers specific to the site you want to amplify. You "paint" the amplicon with a double-strand specific dye, included in the PCR mix. The ds-specific dye integrates itself into the PCR product. In essence, the entire amplicon becomes a probe. This opens up new possibilities for discovery. Either you position the primers very close to either side of the SNP in question (small amplicon genotyping) or amplify a larger region (100–400bp in length) for scanning purposes. For simple genotyping of an SNP, it is easier to just make the amplicon small to minimize the chances you mistake one SNP for another. The melting temperature (Tm) of the entire amplicon is determined and most homozygotes are sufficiently different (in the better instruments) in Tm to genotype. Heterozygotes are even easier to differentiate because they have heteroduplexes generated (refer to the gel-based explanations) which broadens the melt transition and usually gives two discernible peaks. Amplicon melting using a fluorescently-labeled primer has been described, but is less practical than using ds-specific dyes due to the cost of the fluorogenic primer. Scanning of larger amplicons is based on the same principles as outlined above.
During the 2026 legislative session, Moore proposed an additional $150 million in cuts to the DDA as well as a $500,000 cap on the total amount of state funding a single person with a DDA waiver could receive in a year for their health needs. The Maryland Senate reduced these cuts to $126 million and rejected the health services cap, but retained several other cost containment measures proposed by Moore. In May 2025, Moore signed into law a bill requiring insurers to cover vaccinations recommended by the Advisory Committee on Immunization Practices as of December 2024. In September 2025, amid efforts by Health and Human Services Secretary Robert F. Kennedy Jr. to restrict access to vaccines, Maryland joined the Northeast Public Health Collaborative, a coalition of states to coordinate public health guidelines separate from the Centers for Disease Control and Prevention (CDC). During the 2026 legislative session, Moore introduced a bill that would give the Maryland Secretary of Health the ability to issue vaccine recommendations tied to guidance from major medical associations and other states. The bill passed and was signed into law by Moore in April 2026.
==== UPMC Passavant ==== UPMC Passavant is UPMC's tertiary care hospital of Pittsburgh's northern suburbs that consist of two campuses, one in McCandless and another in Cranberry Township with a combined 423 beds. Founded by Lutherans in 1849, Passavant was the first Protestant hospital built in the United States. In 1964, Passavant moved from the City of Pittsburgh to its location in McCandless to serve the communities of northern Allegheny and southern Butler counties. Passavant merged with UPMC in 1997 and in 2002, as part of UPMC's acquisition of St. Francis Medical Center for the conversion of its flagship facility into the new Children's Hospital of Pittsburgh, UPMC converted St. Francis' hospital in Cranberry into a satellite campus of UPMC Passavant. In 2010, a seven-story 188,000 square foot patient pavilion was opened on the McCandless campus bringing total beds there to 399.
PyBOP (benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate) is a reagent used to prepare amides from carboxylic acids and amines in the context of peptide synthesis. It can be prepared from 1-hydroxybenzotriazole and a chlorophosphonium reagent under basic conditions. It is a substitute for the BOP reagent that avoids the formation of the carcinogenic waste product HMPA. Thermal hazard analysis by differential scanning calorimetry (DSC) shows PyBOP is potentially explosive.
Diseases affecting cardiac muscle, known as cardiomyopathies, are the leading cause of death in developed countries. The most common condition is coronary artery disease, in which the blood supply to the heart is reduced. The coronary arteries become narrowed by the formation of atherosclerotic plaques. If these narrowings become severe enough to partially restrict blood flow, the syndrome of angina pectoris may occur. This typically causes chest pain during exertion that is relieved by rest. If a coronary artery suddenly becomes very narrowed or completely blocked, interrupting or severely reducing blood flow through the vessel, a myocardial infarction or heart attack occurs. If the blockage is not relieved promptly by medication, percutaneous coronary intervention, or surgery, then a heart muscle region may become permanently scarred and damaged. Specific cardiomyopathies include: increased left ventricular mass (hypertrophic cardiomyopathy), abnormally large (dilated cardiomyopathy), or abnormally stiff (restrictive cardiomyopathy). Some of these conditions are caused by genetic mutations and can be inherited. Heart muscle can also become damaged despite a normal blood supply. The heart muscle may become inflamed in a condition called myocarditis, most commonly caused by a viral infection but sometimes caused by the body's own immune system. Heart muscle can also be damaged by drugs such as alcohol, long standing high blood pressure or hypertension, or persistent abnormal heart racing.
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.